CARDIOVASCULAR EFFECTS BASED ON MAGNITUDE OF WEIGHT LOSS (WL) IN OBESE/OVERWEIGHT SUBJECTS WITH HYPERTENSION RECEIVING PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE (PHEN/TPM ER)

被引：0

作者：

Bakris, George ^{[1
]}

Davidson, Michael H. ^{[1
]}

Gupta, Alok K. ^{[2
]}

机构：

[1] Univ Chicago, Pritzker Sch Med, ASH Comprehens Hypertens Ctr, Chicago, IL 60637 USA

[2] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA

来源：

JOURNAL OF CLINICAL HYPERTENSION | 2013年 / 15卷 / 07期

关键词：

Phentermine and Topiramate Extended-release; Obesity; Hypertension; Weight loss;

D O I：

暂无

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

引用

页码：517 / 517

页数：1

共 29 条

[21] Amount of cardiometabolic risk reduction is directly associated with magnitude of weight loss with low-dose, controlled-release phentermine/topiramate (PHEN/TPM CR)
Klein, S.
Tam, P.
Peterson, C.
DIABETES OBESITY & METABOLISM, 2010, 12 : 52 - 52
[22] Magnitude of Weight Loss Experienced with a Low-Dose, Controlled-Release Formulation of Phentermine/Topiramate (PHEN/TPM) May Drive Degree of Cardiometabolic Benefit
Gadde, Kishore
Najarian, Thomas
Day, Wesley W.
DIABETES, 2010, 59 : A482 - A483
[23] MAGNITUDE OF WEIGHT LOSS CONFERRED BY CONTROLLED-RELEASE LOW-DOSE PHENTERMINE/TOPIRAMATE (PHEN/TPM CR) DETERMINES EXTENT OF CARDIOMETABOLIC BENEFIT.
Troupin, B.
Hankin, C. S.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S38 - S39
[24] Clinically Meaningful Weight-Loss Outcomes With Low-Dose Controlled-Release Phentermine/Topiramate in Overweight/Obese Subjects
Gadde, Kishore M.
Peterson, Craig
Day, Wesley W.
OBESITY, 2010, 18 : S153 - S153
[25] Low-dose, controlled-release phentermine/topiramate (PHEN/TPM) mediated weight loss causes improvement in lipoproteins and inflammatory biomarkers in overweight patients with comorbidities
Davidson, M.
Tonstad, S.
Bowden, C.
Day, W.
EUROPEAN HEART JOURNAL, 2010, 31 : 999 - 999
[26] LOW-DOSE CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE (PHEN/TPM CR) RESULTS IN SIGNIFICANT WEIGHT LOSS AND IMPROVES ATHEROSCLEROTIC BIOMARKERS IN OVERWEIGHT/OBESE PATIENTS WITH OBESITY-RELATED COMORBIDITIES.
Troupin, B.
Hankin, C. S.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S39 - S39
[27] Diabetes Prevention and Normalization of Fasting Glucose in Subjects with Prediabetes Using Controlled-Release Phentermine/Topiramate (PHEN/TPM CR) in a 2-Year Weight Loss Intervention
Ryan, Donna H.
Garvey, Timothy
Troupin, Barbara
Day, Wesley W.
DIABETES, 2011, 60 : A509 - A509
[28] A Low-Dose, Controlled-Release Formulation of Phentermine/Topiramate (PHEN/TPM) Demonstrates Significant Weight Loss, Clinical Improvement in Overweight/Obese Patients with Type 2 Diabetes Mellitus (T2DM) or Prediabetes
Gadde, Kishore
Najarian, Thomas
Day, Wesley W.
DIABETES, 2010, 59 : A101 - A101
[29] CONTROLLED-RELEASE LOW-DOSE PHENTERMINE/TOPIRAMATE (PHEN/TPM CR) REDUCES WEIGHT, IMPROVES GLYCEMIC MARKERS, AND DECREASES PROGRESSION TO TYPE 2 DIABETES MELLITUS (T2DM) IN OVERWEIGHT AND OBESE PATIENTS WITH OBESITY-RELATED COMORBIDITIES.
Troupin, B.
Hankin, C. S.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S38 - S38

← 1 2 3 →